Blood biomarkers for Alzheimer's disease and related disorders
Acta Neurologica Scandinavica · 2022-07 · 146 (1) · 51-55
DOI: 10.1111/ane.13628 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Acta Neurologica Scandinavica, online erschienen am 25.04.2022. Verfasst von Henrik Zetterberg und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölnd…. Hauptthemen laut MEDLINE: Alzheimer Disease, Neurodegenerative Diseases. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: the Swedish Research Council, the European Research Council, Swedish State Support for Clinical Research.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer's disease (AD) is a progressive neurodegenerative disease and the single commonest cause of dementia. Many other diseases can, however, cause dementia, and differential diagnosis can be challenging, especially in early disease stages. For most neurodegenerative dementias, accumulation of brain pathologies starts many years before clinical onset; the ability to detect these pathologies paves the way for targeted disease-modifying prevention trials. AD is associated with β-amyloid and tau pathologies, which can be quantified using cerebrospinal fluid and imaging biomarkers and, more recently, using highly sensitive blood tests. While for the most part, specific biomarkers of non-AD neurodegenerative dementias are lacking, non-specific biomarkers of neurodegeneration are available. This review summarizes recent advances in the neurodegenerative dementia blood biomarker research and discusses the next steps required for clinical implementation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
- Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
- Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.
- UK Dementia Research Institute at UCL, London, UK.
- Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China.
- Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, UK.
ORCID-Profile: Henrik Zetterberg
Förderung
- the Swedish Research Council
- the European Research Council
- Swedish State Support for Clinical Research
- the Alzheimer Drug Discovery Foundation (ADDF), USA
- the AD Strategic Fund and the Alzheimer's Association
- the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden
- the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE)
- the European Union Joint Programme-Neurodegenerative Disease Research
Zitieren
APA
Zetterberg, H., & Schott, J. M. (2022). Blood biomarkers for Alzheimer's disease and related disorders. Acta Neurologica Scandinavica, 146(1), 51-55. https://doi.org/10.1111/ane.13628
Vancouver
Zetterberg H, Schott JM. Blood biomarkers for Alzheimer's disease and related disorders. Acta Neurologica Scandinavica. 2022;146(1):51-55. doi:10.1111/ane.13628
BibTeX
@article{Zetterberg2022,
author = {Zetterberg, Henrik and Schott, Jonathan M},
title = {Blood biomarkers for Alzheimer's disease and related disorders},
journal = {Acta Neurologica Scandinavica},
year = {2022},
volume = {146},
number = {1},
pages = {51--55},
doi = {10.1111/ane.13628}
}
EUVIMED